PURPOSE OF REVIEW: The approval of teduglutide, a recombinant analog of @entity1 @entity5445 , by the US Food and Drug Administration (Gattex) and the European Medicines Agency (Revestive) has illustrated the potential of selected gut hormones as treatments in @entity1 with @entity5277 and intestinal failure. Gut hormones may improve the structural and functional intestinal adaptation following intestinal resection by decreasing a rapid gastric emptying and hypersecretion, by increasing the intestinal blood flow, and by promoting intestinal growth. This review summarizes the findings from phase 2 and 3 teduglutide studies, and pilot studies employing @entity6757 and agonists for this orphan condition. RECENT FINDINGS: In a 3-week, phase 2, metabolic balance study, teduglutide increased the intestinal wet weight absorption by approximately 700g/day and reduced fecal energy losses by approximately 0.8MJ/day (   200Kcal/day). In two subsequent 24-week, phase 3 studies, teduglutide reduced the need for parenteral support in the same magnitude. Adverse events were mainly of gastrointestinal origin and consistent with the known mechanism of action of teduglutide. Pilot studies suggest that @entity6757 may be less potent. Synergistic effects may be seen by co-treatment with @entity5445 . SUMMARY: Gut hormones promote intestinal adaptation and absorption, decreasing fecal losses, thereby decreasing or even eliminating the need for parenteral support. This will aid the intestinal rehabilitation in these severely disabled @entity5277 @entity1 .

Gut hormones in the treatment of XXXX and intestinal failure.

@entity1 :: ('9606', 'Species') :: ['human', 'patients'] @entity5277 :: ('MESH:D012778', 'Disease') :: ['short-bowel syndrome'] @entity5445 :: ('2641', 'Gene') :: ['glucagon-like peptide (GLP) 2', 'GLP-2'] @entity6757 :: ('100125288', 'Gene') :: ['GLP-1']
@entity5277 :: (MESH:D012778,Disease) :: ['short-bowel syndrome']
